4//SEC Filing
Trevejo Jose M. 4
Accession 0001209191-23-019880
CIK 0001819790other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 6:18 PM ET
Size
9.5 KB
Accession
0001209191-23-019880
Insider Transaction Report
Form 4
Trevejo Jose M.
CHIEF MEDICAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2023-03-15+7,549→ 9,153 total - Sale
Common Stock
2023-03-16$13.43/sh−499$6,702→ 8,654 total - Exercise/Conversion
Restricted Stock Units
2023-03-15−7,549→ 22,648 total→ Common Stock (7,549 underlying)
Footnotes (5)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- [F2]includes 1,604 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022.
- [F3]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F4]Each RSU represents a contingent right to receive one share of the Company's common stock.
- [F5]RSU granted on February 1, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001661539
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 6:18 PM ET
- Size
- 9.5 KB